DeutschNewstral
Article
jdsupra.com on 2019-08-01 18:32
Prosecution History Estoppel Bars Amgen’s Doctrine-of-Equivalents Infringement Claim Against Neulasta (Pegfilgrastim) Biosimilar Maker Coherus
Related news
- Prosecution History Estoppel Bars Amgen’s Infringement Claim Under the Doctrine of Equivalentsjdsupra.com
- Coherus Files Responsive Appellate Brief in Amgen v. Coherus (pegfilgrastim)jdsupra.com
- FDA Approves Sandoz’s Biosimilar Pegfilgrastimjdsupra.com
- FDA Approves Second Pegfilgrastim Biosimilar, a First for Coherusjdsupra.com
- Pfizer Moves to Dismiss Amgen’s Suit Over Proposed Neulasta Biosimilarjdsupra.com
- U.S. Biosimilar Launches: Mylan/Biocon’s Trastuzumab, Sandoz’s Pegfilgrastimjdsupra.com
- Prosecution History Estoppel Bars Infringement Claim Under Doctrine of Equivalentsjdsupra.com
- Coherus Plans to Launch UDENYCA (pegfilgrastim-cbqv) in U.S. in January at 33% Discountjdsupra.com
- Effect of Prosecution History Estoppel on Infringement Claim under Doctrine of Equivalentsjdsupra.com
- Coherus Biosciences Launches UDENYCA (pegfilgrastim-cbqv), and Secures $75 Million Credit Financing to Accelerate Manufacture and Salejdsupra.com
- Doctrine of Equivalents: Prosecution History Estoppel of Care Both Amendment and Argument-Basedjdsupra.com
- Coherus Receives FDA’s Complete Response Letter for its Pegfilgrastim Biosimilarjdsupra.com
- PFDA declines to approve Novartis biosimilar for Amgen’s Neulastapacbiztimes.com
- Analysis of Amgen’s complaint against Sandoz in pegfilgrastim litigationjdsupra.com
- PNovartis biosimilar works as well as Amgen’s Neulastapacbiztimes.com
- PTAB Grants Apotex’s Petition for IPR on Amgen’s Neulasta (Pegfilgrastim) Patentjdsupra.com
- European Commission Approves Pegfilgrastim Biosimilarsjdsupra.com
- Coherus Implements Restructuring Plan Following Complete Response Letter For Its Pegfilgrastim Biosimilarjdsupra.com
- Amgen Sues Pfizer Over Proposed Neulasta Biosimilarjdsupra.com
- IPR Estoppel Strikes Againjdsupra.com